Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
Acquisition Announcement: Impact BioMedical (IBO) has acquired Celios in an all-equity transaction valued at approximately $1.15 million, enhancing its portfolio with advanced air purification technology that supports human health and wellness.
Technological Advancements: The acquisition includes patented filter technology that provides "virtually clean room" air quality, which is portable and user-friendly, aligning with Impact Biomedical's mission to deliver top-tier healthcare solutions.
Trade with 70% Backtested Accuracy
Analyst Views on IBO
About IBO
About the author
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.
Impact Biomedical Inc (IBO) Announces Issuance of US Patent for 3F™
Patent Announcement: Impact Biomedical Inc. has received U.S. patent No. 12,357,584 B2 for a method to control infectious diseases using functional fragrances from its 3F™ technology platform.
Composition Details: The patented compositions include plant-derived constituents with antibacterial and antiviral properties, potentially effective against pathogens like E. coli, MRSA, influenza, and tuberculosis.
Market Potential: The global infectious disease market is expected to grow significantly, from $21.7 billion in 2024 to $34 billion by 2033, highlighting the demand for innovative healthcare solutions.
Company Commitment: IBO's CEO emphasized the company's dedication to developing unique technologies to address healthcare needs and is actively seeking partnerships to bring their 3F™ technology to market.
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
BlackBerry's Financial Performance: BlackBerry Limited's shares rose 14.7% in pre-market trading after reporting first-quarter earnings of two cents per share, surpassing analyst expectations, and increasing its fiscal 2026 revenue guidance to between $508 million and $538 million.
Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with NaaS Technology Inc. surging 40.6% and XTI Aerospace, Inc. dropping 31.2% following their respective announcements and market reactions.
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.
Top Midday Gainers
Merger Announcement: Impact BioMedical (IBO) has announced a merger with the Hong Kong-based pharmaceutical group Dr.
Portfolio Access: Users need to sign in to access their portfolio related to this announcement.
Impact BioMedical Stock Is Soaring Monday: What's Going On?
Merger Announcement: Impact Biomedical, Inc. has entered into a strategic merger agreement with Dr. Ashleys, resulting in a reverse merger where Dr. Ashleys will acquire Impact Biomedical and the new entity will be listed as "Dr Ashleys Limited" on the NYSE American.
Stock Performance: Following the announcement, Impact Biomedical's stock surged by 373.6%, reaching $1.71, reflecting significant investor interest in the potential growth from the merger.
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.
Impact Biomedical Inc (IBO) Announces Issuance of US Patent for 3F™
Patent Announcement: Impact Biomedical Inc. has received U.S. patent No. 12,357,584 B2 for a method to control infectious diseases using functional fragrances from its 3F™ technology platform.
Composition Details: The patented compositions include plant-derived constituents with antibacterial and antiviral properties, potentially effective against pathogens like E. coli, MRSA, influenza, and tuberculosis.
Market Potential: The global infectious disease market is expected to grow significantly, from $21.7 billion in 2024 to $34 billion by 2033, highlighting the demand for innovative healthcare solutions.
Company Commitment: IBO's CEO emphasized the company's dedication to developing unique technologies to address healthcare needs and is actively seeking partnerships to bring their 3F™ technology to market.
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
BlackBerry's Financial Performance: BlackBerry Limited's shares rose 14.7% in pre-market trading after reporting first-quarter earnings of two cents per share, surpassing analyst expectations, and increasing its fiscal 2026 revenue guidance to between $508 million and $538 million.
Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with NaaS Technology Inc. surging 40.6% and XTI Aerospace, Inc. dropping 31.2% following their respective announcements and market reactions.
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.
Top Midday Gainers
Merger Announcement: Impact BioMedical (IBO) has announced a merger with the Hong Kong-based pharmaceutical group Dr.
Portfolio Access: Users need to sign in to access their portfolio related to this announcement.
Impact BioMedical Stock Is Soaring Monday: What's Going On?
Merger Announcement: Impact Biomedical, Inc. has entered into a strategic merger agreement with Dr. Ashleys, resulting in a reverse merger where Dr. Ashleys will acquire Impact Biomedical and the new entity will be listed as "Dr Ashleys Limited" on the NYSE American.
Stock Performance: Following the announcement, Impact Biomedical's stock surged by 373.6%, reaching $1.71, reflecting significant investor interest in the potential growth from the merger.
